Thrombocytopenia (severe)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

508 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Myelofibrosis Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp48

Triage and Immediate Priorities

›Immediate stabilization

›Airway compromise from oropharyngeal bleeding

›Early airway planning if active upper airway bleeding

›Hemodynamic instability from hemorrhage

›Massive transfusion protocol activation if ongoing shock

›Life threatening bleeding sites

›Intracranial hemorrhage concern

›Gastrointestinal hemorrhage concern

›Hemoptysis concern

›Postpartum or gynecologic hemorrhage concern

›High risk platelet thresholds

›Platelets less than 10 x 10^9/L

›Platelets less than 20 x 10^9/L with fever or sepsis

›Platelets less than 50 x 10^9/L with active bleeding or planned invasive procedure

Rapid Confirmation and Reversible Causes

›Rapid confirmation

›Pseudothrombocytopenia exclusion

›EDTA platelet clumping on smear

›Repeat CBC in citrate tube if clumping suspected

›Baseline comparison

›Prior platelet trend if available

›Acute drop greater than 50 percent from baseline

›Medication and exposure stop points

›Heparin exposure within 5 to 14 days or within 24 hours with prior exposure

›Recent new drug within 1 to 2 weeks

Bleeding Risk Stratification

›Bleeding phenotype

›Mucocutaneous bleeding pattern

›Petechiae

›Purpura

›Epistaxis

›Gingival bleeding

›Deep tissue bleeding pattern

›Hemarthrosis

›Retroperitoneal bleeding

›Intramuscular hematoma

›Red flag symptoms

›New severe headache

›Focal neurologic deficit

›Melena or hematochezia

›Hematemesis

Immediate Consult and Escalation Triggers

›Escalation triggers

›Platelets less than 10 x 10^9/L with any bleeding

›Hematology consult

›Suspected thrombotic microangiopathy

›Plasma exchange capable center coordination

›Suspected heparin induced thrombocytopenia with thrombosis

›Immediate anticoagulation strategy change

›Suspected DIC with active bleeding

›Critical care involvement

02History/hx57

Presenting Features and Timeline

›Symptom pattern

›Bleeding onset and progression

›Time of first petechiae or bruising

›Time of first mucosal bleeding

›Thrombotic symptoms

›Limb swelling or pain

›Chest pain or dyspnea

›Focal neurologic deficit

›Constitutional symptoms

›Fever

›Weight loss

›Night sweats

Exposures and Medications

›Exposure review

›Heparin exposure

›Unfractionated heparin

›Low molecular weight heparin

›Antiplatelet agents

›Aspirin

›P2Y12 inhibitors

›Anticoagulants

›DOACs

›Warfarin

›Drugs associated with immune thrombocytopenia

›TMP SMX

›Vancomycin

›Linezolid

›Quinine

›Valproate

›Carbamazepine

›Alcohol use and binge pattern

›Recent heavy intake

Medical and Family Context

›Comorbid risk

›Liver disease

›Portal hypertension history

›Prior variceal bleed

›Autoimmune disease

›SLE features

›Antiphospholipid syndrome history

›Malignancy or marrow disease

›Prior chemo or radiation

›Unexplained cytopenias

›Infection risk

›HIV risk

›Hepatitis C risk

›Recent viral syndrome

›Family history

›Inherited thrombocytopenia

›Lifelong low platelets

›Bleeding since childhood

Pregnancy and Postpartum Context

›Pregnancy related context

›Gestational age

›Third trimester onset

›Postpartum onset

›Preeclampsia features

›Headache

›Visual symptoms

›RUQ pain

03Physical Exam/exam42

Bleeding and Skin Findings

›Mucocutaneous exam

›Petechiae distribution

›Dependent areas

›Generalized

›Purpura and ecchymoses

›Disproportionate bruising without trauma

›Mucosal bleeding

›Oral bullae

›Gingival oozing

›Epistaxis severity

Hemodynamic and End Organ Assessment

›Vital signs and perfusion

›Hypotension

›Hemorrhagic shock pattern

›Tachycardia

›Compensatory response

›Fever

›Sepsis trigger

›Neurologic exam

›Mental status change

›Intracranial hemorrhage concern

›TTP concern

›Focal deficits

›Stroke concern

Etiology Clues

›Systemic clues

›Hepatosplenomegaly

›Hypersplenism pattern

›Hematologic malignancy concern

›Lymphadenopathy

›Lymphoma concern

›HIV concern

›Jaundice or scleral icterus

›Hemolysis or liver disease

›Pregnancy hypertension signs

›Edema

›Hyperreflexia

PITFALLS

›Common pitfalls

›Petechiae without platelet confirmation

›Consider vasculitis mimics

›Missing thrombotic microangiopathy

›Normal appearing skin does not exclude TTP

›Assuming ITP in all isolated thrombocytopenia

›Smear and hemolysis markers required

04Differential Diagnosis/ddx45

Life Threatening Causes

›Immediate threats

›Thrombotic thrombocytopenic purpura

›ICD-10 M31.1

›SNOMED CT thrombotic thrombocytopenic purpura

›Disseminated intravascular coagulation

›ICD-10 D65

›SNOMED CT disseminated intravascular coagulation

›Heparin induced thrombocytopenia

›ICD-10 D75.82

›SNOMED CT heparin induced thrombocytopenia

›Acute leukemia

›ICD-10 C95.00

›SNOMED CT acute leukemia

›Catastrophic antiphospholipid syndrome

›ICD-10 D68.61

›SNOMED CT antiphospholipid syndrome

Common Non Thrombotic Causes

›Production or sequestration

›Immune thrombocytopenia

›ICD-10 D69.3

›SNOMED CT immune thrombocytopenia

›Drug induced immune thrombocytopenia

›ICD-10 D69.59

›SNOMED CT drug induced thrombocytopenia

›Hypersplenism

›ICD-10 D73.1

›SNOMED CT hypersplenism

›Alcohol related thrombocytopenia

›ICD-10 D69.6

›Viral associated thrombocytopenia

›HIV

›HCV

Pregnancy Associated Causes

›Pregnancy and postpartum

›Gestational thrombocytopenia

›ICD-10 O99.11

›Preeclampsia with severe features

›ICD-10 O14.1

›HELLP syndrome

›ICD-10 O14.2

›Acute fatty liver of pregnancy

›ICD-10 O26.61

Mimics and Measurement Issues

›Artifacts and mimics

›Pseudothrombocytopenia

›EDTA dependent clumping

›Dilutional thrombocytopenia

›Massive transfusion related

05Laboratory Tests/lt58

Core Hematology

›Platelet confirmation and morphology

›CBC with indices

›Platelet count trend and severity

›Concurrent anemia

›Concurrent leukopenia

›Peripheral blood smear

›Platelet clumping

›Schistocytes

›Blasts

Hemolysis and Thrombotic Microangiopathy Set

›Hemolysis evaluation

›LDH

›Elevated supports microangiopathic hemolysis

›Haptoglobin

›Low supports hemolysis

›Total bilirubin

›Indirect predominance supports hemolysis

›Reticulocyte count

›Elevated supports hemolysis

Coagulation and Consumptive Process Set

›Coagulopathy evaluation

›PT INR

›Prolonged supports DIC or liver dysfunction

›aPTT

›Prolonged supports DIC or factor deficiency

›Fibrinogen

›Low supports DIC

›D dimer

›Elevated supports DIC

Organ Function and Triggers

›End organ assessment

›Creatinine and urea

›Kidney injury supports TTP HUS or sepsis

›AST ALT ALP

›Liver dysfunction contribution

›Electrolytes

›Supportive metabolic context

›Lactate mmol/l

›Shock severity marker

Targeted Etiology Tests

›Secondary cause evaluation

›HIV antigen antibody

›Secondary ITP association

›Hepatitis C serology

›Secondary ITP association

›Pregnancy test

›Pregnancy related etiologies

›Direct antiglobulin test

›Evans syndrome support

›Vitamin B12 and folate

›Marrow and ineffective hematopoiesis context

Transfusion and Procedural Readiness

›Blood bank

›Type and screen

›Anticipated transfusion

›Crossmatch

›Active hemorrhage pathway

PITFALLS

›Lab pitfalls

›Isolated thrombocytopenia without smear review

›Missed clumping

›Missed schistocytes

›DIC evaluation without fibrinogen

›Incomplete consumptive assessment

06Diagnostic Tests/dt42

Scoring Systems

›Risk stratification tools

›PLASMIC score for severe ADAMTS13 deficiency

›Platelets less than 30 x 10^9/L

›Hemolysis evidence

›No active cancer

›No solid organ or stem cell transplant

›MCV less than 90 fL

›INR less than 1.5

›Creatinine less than 176 micromol/l

›High score supports immediate plasma exchange before ADAMTS13 result

›4Ts score for HIT pretest probability

›Thrombocytopenia magnitude

›Timing of platelet fall

›Thrombosis or other sequelae

›oTher causes unlikely

›Intermediate or high score supports non heparin anticoagulation while testing

›ISTH DIC score

›Platelet count points

›D dimer or fibrin degradation products points

›PT prolongation points

›Fibrinogen points

MRI

›MRI applications

›Brain MRI for neurologic symptoms with non diagnostic CT

›Posterior reversible encephalopathy syndrome in pregnancy hypertension

›Ischemic stroke evaluation in HIT or APS

›Spine MRI for suspected spinal epidural hematoma

›New back pain with neurologic deficit

›CT applications

›Non contrast CT head for neurologic symptoms or head trauma

›Low threshold with platelets less than 20 x 10^9/L and headache

›CT abdomen pelvis for suspected retroperitoneal hemorrhage

›Flank pain

›Unexplained anemia

›CT pulmonary angiography when PE suspected in HIT

›Dyspnea with thrombosis concern

Ultrasound

›Ultrasound applications

›POCUS for hemodynamic instability

›Free fluid assessment in hemorrhagic shock

›Lower extremity venous ultrasound in suspected HIT thrombosis

›Leg swelling or pain

›RUQ ultrasound for splenomegaly context

›Hypersplenism support

07Disposition/dispo21

Admission and Level of Care

›Level of care selection

›ICU indications

›Active major bleeding

›Suspected TTP or other thrombotic microangiopathy

›Suspected DIC with organ dysfunction

›Platelets less than 10 x 10^9/L with high risk features

›Stepdown or ward indications

›Stable ITP with platelets 10 to 30 x 10^9/L and no major bleeding after treatment initiation

›Drug induced thrombocytopenia with improving counts and no bleeding

Transfer Criteria

›Transfer triggers

›Need for plasma exchange

›No local capability

›Neurosurgical capability for intracranial hemorrhage

›Platelet guided transfusion strategy required

Discharge Criteria

›Discharge considerations

›Stable vitals

›No active bleeding

›Platelets improving and above threshold for outpatient safety

›Typically greater than or equal to 20 to 30 x 10^9/L for reliable follow up and no bleeding

›Clear etiology and plan

›Hematology follow up arranged within 24 to 72 hours

08Treatment/t98

Platelet Transfusion Thresholds and Strategy

›Platelet transfusion framework

›Prophylaxis threshold

›Platelets less than 10 x 10^9/L

›Transfuse 1 adult apheresis unit

›Recheck platelet count 15 to 60 minutes after completion

›Fever or sepsis threshold

›Platelets less than 20 x 10^9/L

›Transfuse 1 adult apheresis unit

›Treat underlying infection concurrently

›Active major bleeding threshold

›Platelets less than 50 x 10^9/L

›Transfuse 1 to 2 adult apheresis units

›Target platelets greater than or equal to 50 x 10^9/L

›Critical site bleeding threshold

›Intracranial hemorrhage or neurosurgery

›Target platelets greater than or equal to 100 x 10^9/L

›Class IIa recommendation in many neurocritical care pathways for critical site bleeding support

Immune Thrombocytopenia First Line

›Suspected ITP treatment

›Corticosteroids

›Dexamethasone 40 mg PO or IV daily for 4 days

›Preferred for rapid response pathway

›Prednisone 1 mg per kg per day PO

›Typical duration 1 to 2 weeks then taper

›IVIG for faster rise or significant bleeding

›IVIG 1 g per kg IV daily for 1 to 2 days

›Response often within 24 to 48 hours

›Platelet transfusion caveat

›If life threatening bleeding then transfuse platelets with IVIG and steroids

›Short lived increment expected

Thrombotic Thrombocytopenic Purpura

›Suspected TTP pathway

›Plasma exchange

›Initiate immediately if high clinical suspicion or high PLASMIC score

›Daily exchanges until platelet recovery and hemolysis resolves

›Corticosteroids adjunct

›Methylprednisolone 1 mg per kg per day IV

›Alternative high dose pulse per hematology

›Caplacizumab consideration

›Early use reduces time to platelet normalization in trials

›Hematology directed initiation

›Platelet transfusion avoidance

›Avoid routine platelet transfusion

›Consider only for life threatening bleeding or urgent invasive procedure

Heparin Induced Thrombocytopenia

›Suspected HIT management

›Stop all heparin products

›Flushes and line locks included

›Non heparin anticoagulation if intermediate or high 4Ts

›Argatroban IV infusion

›Initiate per institutional protocol

›aPTT guided titration

›Bivalirudin IV infusion

›Preferred in some procedural settings

›Fondaparinux SC

›Off label option with stable renal function

›Warfarin precautions

›Avoid starting warfarin until platelets recover

›Risk of venous limb gangrene

›HIT testing

›PF4 ELISA followed by functional assay when available

Disseminated Intravascular Coagulation

›DIC supportive treatment

›Treat underlying trigger

›Sepsis source control

›Obstetric complication management

›Malignancy management coordination

›Platelets for bleeding or procedures

›Active bleeding with platelets less than 50 x 10^9/L

›Transfuse platelets

›Fibrinogen support

›Fibrinogen less than 1.5 g/L with bleeding

›Cryoprecipitate per institutional dosing

›Coagulation factor support

›Prolonged PT INR with bleeding

›Plasma per institutional protocol

Adjunctive Hemorrhage Control

›Antifibrinolytic therapy

›Tranexamic acid

›Major traumatic bleeding or postpartum hemorrhage per local protocols

›Time sensitive early administration

›Topical hemostatics

›Nasal packing adjuncts for epistaxis

›Platelet function and uremia adjunct

›Desmopressin for suspected platelet dysfunction

›Uremia associated bleeding

›Antiplatelet associated surgical bleeding per specialist input

Procedure Related Targets

›Platelet targets for procedures

›Central venous catheter

›Target platelets greater than or equal to 20 x 10^9/L in many institutional pathways

›Lumbar puncture

›Target platelets greater than or equal to 50 x 10^9/L in many institutional pathways

›Major surgery

›Target platelets greater than or equal to 50 x 10^9/L

›Neurosurgery

›Target platelets greater than or equal to 100 x 10^9/L

Antiplatelet Associated Intracranial Hemorrhage Caveat

›Platelet transfusion in spontaneous ICH on antiplatelets

›Non surgical spontaneous ICH

›Avoid routine platelet transfusion

›Class III harm recommendation in some stroke guidelines based on PATCH trial

›Planned neurosurgical intervention

›Platelet transfusion often used to optimize hemostasis

›Specialist directed strategy

09Special Populations/sp29

Pregnancy

›Pregnancy considerations

›Gestational thrombocytopenia pattern

›Mild thrombocytopenia usually greater than 70 x 10^9/L

›No maternal bleeding

›Preeclampsia HELLP evaluation

›Hypertension and proteinuria

›AST ALT elevation

›Hemolysis markers

›Treatment safety

›IVIG compatible with pregnancy

›Corticosteroids compatible with pregnancy

›Delivery anesthesia planning

›Neuraxial anesthesia platelet thresholds per obstetric anesthesia policy

Geriatric

›Older adult considerations

›Polypharmacy

›Higher likelihood of drug induced thrombocytopenia

›Falls and occult trauma risk

›Lower threshold for CT head with low platelets

›Malignancy and marrow failure prevalence

›Smear blasts and pancytopenia triggers

Pediatrics

›Pediatric considerations

›Acute ITP common after viral illness

›Observation reasonable if no significant bleeding and stable

›Weight based dosing

›IVIG 1 g per kg dosing

›Steroid dosing per pediatric protocol

›HUS considerations

›Diarrhea associated bloody stool

›Creatinine elevation and hemolysis markers

10Background/b30

Epidemiology

›Epidemiology overview

›Severe thrombocytopenia commonly defined as platelets less than 20 x 10^9/L

›Spontaneous bleeding risk rises markedly below 10 x 10^9/L

›ITP common cause of isolated thrombocytopenia

›Often mucocutaneous bleeding phenotype

›HIT uncommon but high thrombosis risk

›Platelet nadir often 20 to 100 x 10^9/L rather than single digits

Pathophysiology

›Mechanisms

›Decreased production

›Marrow suppression or infiltration

›Nutritional deficiency

›Increased destruction

›Immune mediated

›Drug dependent antibodies

›Consumption

›DIC

›TTP microvascular platelet rich thrombi

›Sequestration

›Splenomegaly related pooling

Therapeutic Considerations

›Treatment principles

›Treat the cause while preventing hemorrhage

›Platelet transfusion effectiveness varies by mechanism

›ITP

›Steroids and IVIG increase platelet count via immune modulation

›TTP

›Plasma exchange removes autoantibodies and replenishes ADAMTS13

›Delay in plasma exchange associated with high mortality

›HIT

›Thrombosis driven by platelet activation

›Platelet transfusion usually avoided unless bleeding

11Patient Discharge Instructions/pdi21

copy discharge instructions

›Discharge instructions

›Diagnosis and expectations

›Low platelet count increases bleeding risk

›Most bruising and petechiae improve as platelets recover

›Medication and activity guidance

›Avoid aspirin and NSAIDs unless specifically instructed

›Avoid contact sports and high fall risk activities until cleared

›Return now for

›Any head injury

›Severe headache

›Weakness

›Confusion

›Vomiting blood

›Black stools

›Blood in urine

›Heavy vaginal bleeding

›Shortness of breath or chest pain

›New leg swelling or pain

›Follow up plan

›Hematology follow up within 24 to 72 hours if arranged

›Repeat blood work as directed

12References/r17

Clinical Guidelines and Consensus

›Guideline sources

›American Society of Hematology guidelines on immune thrombocytopenia

›Steroids and IVIG as first line for significant bleeding or very low platelets

›American Society of Hematology guidelines on heparin induced thrombocytopenia

›4Ts pretest probability framework

›Non heparin anticoagulation when intermediate or high probability

›International Society on Thrombosis and Haemostasis guidance on DIC

›ISTH DIC scoring system

›Supportive transfusion for bleeding and low fibrinogen

Evidence Based Studies and Tools

›Key evidence

›PLASMIC score derivation and validation studies for predicting severe ADAMTS13 deficiency

›Supports empiric plasma exchange in high risk presentations

›PATCH trial on platelet transfusion in antiplatelet associated spontaneous intracerebral hemorrhage

›Signal of harm in non surgical patients

›AABB platelet transfusion guidance

›Prophylactic transfusion threshold around 10 x 10^9/L in stable patients

›Higher targets for procedures and critical bleeding sites

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.